secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001493152-25-018512
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq notifies Aspire Biopharma of delisting for MVLS and bid price non-compliance; company appeals
--------------------------------------------------------------------------------

- On Oct 15, 2025, Nasdaq Staff notified the Company of delisting due to failure to comply with the MVLS Rule ($50M minimum) and Bid Price Rule ($1.00 minimum).
- The Company failed to regain compliance within the 180-day period that ended on October 13, 2025.
- The Company requested a hearing before the Nasdaq Hearings Panel and paid a $20,000 fee, which stays the suspension pending the Panel's decision.
- The Company will present a plan to regain compliance and may request an extension of up to 180 additional days.
- There is no assurance that the Panel will grant continued listing or that compliance can be regained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225018512/0001493152-25-018512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225018512/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer